A clinical trial to assess the therapeutic efficacy of dual PD-1/LAG3 blockade in metastatic UM with nivolumab/relatlimab (Nivo/Rela)
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Nivolumab/relatlimab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 20 Jan 2025 New trial record